- 1, Inability or unwillingness to provide written informed consent, 2, eGFR＜30ml/min/1.73m2, 3, Subjects who have previously failed both MMF (or other forms of mycophenolate) induction therapies, 4, Subjects who received an induction therapy with CTX or MMF within 3 months prior to the planned initiation of the current induction for the study, 5, Have severe active central nervous system (CNS) lupus (including seizures, psychosis, organic brain syndrome, cerebrovascular accident [CVA], cerebritis, or CNS vasculitis) requiring therapeutic intervention within 60 days of baseline (Day 0), 6, Have acute or chronic infection requiring management based on the investigator's opinion, 7, Pregnant, nursing or under unreliable contraceptive method, 8, Subjects who have been on continuous dialysis starting >2 weeks before randomization into the induction phase and/or continuous dialysis with an anticipated duration >8 weeks, 9, Have a history of kidney transplant or a plan of kidney transplant, 10, Known hypersensitivity or contraindication to any drug products or any component of these drug products they plan to receive (e.g. Artesunate, CTX, MMF, AZA, corticosteroids), 11, Have severe acute or chronic diseases (e.g. cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological or infectious diseases) which, in the opinion of the principal investigator, could confound the results of the study or put the subject at under risk, 12, Have a history of malignant neoplasm within the last 5 years, except for adequately treated carcinoma in situ of the uterine cervix, 13, Recruited by other trial and/or use study agent within 4 weeks.